Claims
- 1. A heteroaromatic ring-fused cyclopentene derivative of the formula: ##STR27## wherein each of Ar.sup.1 and Ar.sup.2 is independently a phenyl group, a thienyl group, a pyridyl group, an indolyl group, a benzofuranyl group or a dihydrobenzofuranyl group wherein an optional hydrogen atom(s) on the aromatic ring may be replaced with 1 to 4 groups selected from the group consisting of a halogen atom, a hydroxyl group, an amino group, a carboxyl group, a C.sub.1 -C.sub.6 alkoxycarbonyl group, a mono- or di- C.sub.1 -C.sub.6 alkylaminocarbonyl group, a carbamoyl group, a tetrazol-5-yl group, a methylenedioxy group, a C.sub.1 -C.sub.6 alkoxy group, a C.sub.2 -C.sub.6 alkenyloxy group, a mono- or di- C.sub.1 -C.sub.6 alkylamino group, a C.sub.1 -C.sub.6 alkyl group, a C.sub.2 -C.sub.6 alkenyl group and a C.sub.2 -C.sub.6 alkynyl group (provided that the C.sub.1 -C.sub.6 alkoxy group, C.sub.2 -C.sub.6 alkenyloxy group, mono- or di- C.sub.1 -C.sub.6 alkylamino group, C.sub.1 -C.sub.6 alkyl group, C.sub.2 -C.sub.6 alkenyl group and C.sub.2 -C.sub.6 alkynyl group may be substituted by 1 to 3 groups selected from the group consisting of a phenyl group, a pyridyl group, an imidazolyl group, a hydroxyl group, a C.sub.1 -C.sub.6 alkoxy group, an amino group, a mono- or di- C.sub.1 -C.sub.6 alkylamino group, a hydroxy C.sub.1 -C.sub.6 alkylcarbonyl group, a C.sub.1 -C.sub.6 acyloxy C.sub.1 -C.sub.6 alkylcarbonyl group, a carboxy C.sub.1 -C.sub.6 alkoxycarbonyl group, a carboxy C.sub.1 -C.sub.6 alkoxycarbonyl C.sub.1 -C.sub.6 alkoxycarbonyl group, a C.sub.1 -C.sub.6 alkoxycarbonyl group, a mono- or di- C.sub.1 -C.sub.6 alkylaminocarbonyl group, a carbamoyl group, a C.sub.1 -C.sub.6 alkylsulfonylaminocarbonyl group, a tetrazol-5-yl-aminocarbonyl group, a carboxyl group, SO.sub.3 H, PO.sub.3 H.sub.2, a tetrazol-5-yl group, a 2-oxo-3H-1,2,3,5-oxathiadiazol-4-yl group and a 5-oxo-4H-1,2,4-oxadiazol-3-yl group (provided that when a hydroxyl group and a carboxyl group are selected as substituents, they may together form a lactone ring));
- each of R.sup.1, R.sup.2 and R.sup.3 is independently a hydrogen atom, a hydroxyl group or a C.sub.1 -C.sub.6 alkyl group, or R.sup.1 and R.sup.2, or R.sup.2 and R.sup.3 together form a single bond;
- Y is a group of --CO--R.sup.4 (wherein R.sup.4 is a hydroxyl group, an amino group, a C.sub.1 -C.sub.6 alkoxy group, a mono- or di- C.sub.1 -C.sub.6 alkylamino group, a C.sub.1 -C.sub.6 alkylsulfonylamino group, an arylsulfonylamino group or an aryl C.sub.1 -C.sub.6 alkylsulfonylamino group wherein an optional hydrogen atom(s) on the aryl ring may be replaced with a C.sub.1 -C.sub.6 alkyl group), SO.sub.3 H, PO.sub.3 H.sub.2, a tetrazol-5-yl group, a 2-oxo-3H-1,2,3,5-oxathiadiazol-4-yl group or a 5-oxo-4H-1,2,4-oxadiazol-3-yl-group; and
- A is a group which forms together with the adjacent carbon-carbon double bond a pyridine, pyrimidine, pyridazine, pyrazine or thiazole ring; provided that optional 1 or 2 hydrogen atoms on the heteroaromatic ring may be replaced with a hydroxyl group, an amino group, a C.sub.1 -C.sub.6 alkoxy group, a C.sub.1 -C.sub.6 alkylthio group, a halogen atom, a cyano group, a nitro group, a mono- or di- C.sub.1 -C.sub.6 alkylamino group which may be substituted by a hydroxyl group at the alkyl moiety; a C.sub.3 -C.sub.8 cycloalkylamino group which may be substituted by a hydroxyl group at the alkyl or alkylene moiety, a C.sub.3 -C.sub.8 cycloalkyl C.sub.1 -C.sub.6 alkylamino group which may be substituted by a hydroxyl group at the alkyl or alkylene moiety an N-(C.sub.1 -C.sub.6 alkyl)-N-(C.sub.3 -C.sub.8 cycloalkyl)amino group which may be substituted by a hydroxyl group at the alkyl or alkylene moiety, an N-(C.sub.1 -C.sub.6 alkyl)-N-(aroyl)amino group which may be substituted by a hydroxyl group at the alkyl moiety, a C.sub.4 -C.sub.7 cyclic imino group which may be substituted by a hydroxyl group at the alkylene moiety, a carboxyl group, a C.sub.1 -C.sub.6 alkoxycarbonyl group, a formyl group, a C.sub.2 -C.sub.6 alkanoyl group, an aroyl group, or a C.sub.1 -C.sub.6 alkyl group, C.sub.3 -C.sub.8 cycloalkyl group, C.sub.3 -C.sub.8 cycloalkyl C.sub.1 -C.sub.6 alkyl group, C.sub.2 -C.sub.6 alkenyl group or C.sub.2 -C.sub.6 alkynyl group which may be substituted by 1 to 3 substituents selected from the group consisting of a hydroxyl group, an amino group, a C.sub.1 -C.sub.6 alkoxy group and a mono- or di- C.sub.1 -C.sub.6 alkylamino group, and when the heteroaromatic ring includes one or more nitrogen atoms, the nitrogen atom(s) may be oxidized to form an N-oxide group;
- or a pharmaceutically acceptable salt thereof.
- 2. A heteroaromatic ring-fused cyclopentene derivative of claim 1, wherein A is a group which forms together with the adjacent carbon-carbon double bond a substituted or unsubstituted pyridine, pyrimidine, pyridazine, pyrazine or thiazole ring; each of Ar.sup.1 and Ar.sup.2 is independently a phenyl group, a thienyl group or a dihydrobenzofuranyl group wherein an optional hydrogen atom(s) on the aromatic ring may be replaced with 1 to 4 groups selected from the group consisting of a halogen atom, a hydroxyl group, an amino group, a methylenedioxy group, a C.sub.1 -C.sub.6 alkoxy group, a C.sub.2 -C.sub.6 alkenyloxy group, a mono- or di- C.sub.1 -C.sub.6 alkylamino group, a C.sub.1 -C.sub.6 alkyl group, a C.sub.2 -C.sub.6 alkenyl group and a C.sub.2 -C.sub.6 alkynyl group (provided that the said C.sub.1 -C.sub.6 alkoxy group, C.sub.2 -C.sub.6 alkenyloxy group, mono- or di- C.sub.1 -C.sub.6 alkylamino group, C.sub.1 -C.sub.6 alkyl group, C.sub.2 -C.sub.6 alkenyl group and C.sub.2 -C.sub.6 alkynyl group may be substituted by 1 to 3 groups selected from the group consisting of a phenyl group, a pyridyl group, an imidazolyl group, a hydroxyl group, a C.sub.1 -C.sub.6 alkoxy group, an amino group, a mono- or di- C.sub.1 -C.sub.6 alkylamino group, a hydroxy C.sub.1 -C.sub.6 alkylcarbonyl group, a C.sub.1 -C.sub.6 acyloxy C.sub.1 -C.sub.6 alkylcarbonyl group, a carboxy C.sub.1 -C.sub.6 alkoxycarbonyl group, a carboxy C.sub.1 -C.sub.6 alkoxycarbonyl C.sub.1 -C.sub.6 alkoxycarbonyl group, a C.sub.1 -C.sub.6 alkoxycarbonyl group, a mono- or di- C.sub.1 -C.sub.6 alkylaminocarbonyl group, a carbamoyl group, a C.sub.1 -C.sub.6 alkylsulfonylaminocarbonyl group, a tetrazol-5-ylaminocarbonyl group, a carboxyl group, a tetrazol-5-yl group, a 2-oxo-3H-1,2,3,5-oxathiadiazol-4-yl group and a 5-oxo-4H-1,2,4-oxadiazol-3-yl group (provided that when a hydroxyl group and a carboxyl group are selected as the substituents, they may together form a lactone ring)); or a pharmaceutically acceptable salt thereof.
- 3. A heteroaromatic ring-fused cyclopentene derivative of claim 1, wherein A is a group which forms together with the adjacent carbon-carbon double bond a substituted or unsubstituted pyridine ring; or a pharmaceutically acceptable salt thereof.
- 4. A heteroaromatic ring-fused cyclopentene derivative of claim 2, wherein A is a group which forms together with the adjacent carbon-carbon double bond, a pyridine ring; or a pharmaceutically acceptable salt thereof.
- 5. A heteroaromatic ring-fused cyclopentene derivative of claim 1, wherein A is a group which forms together with the adjacent carbon-carbon double bond a substituted or unsubstituted pyrimidine ring; or a pharmaceutically acceptable salt thereof.
- 6. A heteroaromatic ring-fused cyclopentene derivative of claim 1, wherein A is a group which forms together with the adjacent carbon-carbon double bond a substituted or unsubstituted pyridazine ring; or a pharmaceutically acceptable salt thereof.
- 7. A heteroaromatic ring-fused cyclopentene derivative of claim 1, wherein A is a group which forms together with the adjacent carbon-carbon double bond a substituted or unsubstituted pyrazine ring; or a pharmaceutically acceptable salt thereof.
- 8. A heteroaromatic ring-fused cyclopentene derivative of claim 1, wherein A is a group which forms together with the adjacent carbon-carbon double bond a substituted or unsubstituted thiazole ring; or a pharmaceutically acceptable salt thereof.
- 9. A drug composition for the treatment of disorders such as hypertension, pulmonary hypertension, Raynaud's disease, acute renal failure, myocardial infarction, angina pectoris, cerebral infarction, cerebral vasospasm, arteriosclerosis, asthma, gastric ulcer, diabetes, restenosis, prostatauxe, endotoxin shock, endotoxin-induced multiple organ failure or disseminated intravascular coagulation, and/or cyclosporin-induced renal failure or hypertension, which contains a heteroaromatic ring-fused cyclopentene derivative of claim 1, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
- 10. A drug composition for the treatment of disorders such as hypertension, pulmonary hypertension, Raynaud's disease, acute renal failure, myocardial infarction, angina pectoris, cerebral infarction, cerebral vasospasm, arteriosclerosis, asthma, gastric ulcer, diabetes, restenosis, prostatauxe, endotoxin shock, endotoxin-induced multiple organ failure or disseminated intravascular coagulation, and/or cyclosporin-induced renal failure or hypertension, which contains a heteroaromatic ring-fused cyclopentene derivative of claim 2 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
- 11. A drug composition for the treatment of disorders such as hypertension, pulmonary hypertension, Raynaud's disease, acute renal failure, myocardial infarction, angina pectoris, cerebral infarction, cerebral vasospasm, arteriosclerosis, asthma, gastric ulcer, diabetes, restenosis, prostatauxe, endotoxin shock, endotoxin-induced multiple organ failure or disseminated intravascular coagulation, and/or cyclosporin-induced renal failure or hypertension, which contains a heteroaromatic ring-fused cyclopentene derivative of claim 3 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
- 12. A drug composition for the treatment of disorders such as hypertension, pulmonary hypertension, Raynaud's disease, acute renal failure, myocardial infarction, angina pectoris, cerebral infarction, cerebral vasospasm, arteriosclerosis, asthma, gastric ulcer, diabetes, restenosis, prostatauxe, endotoxin shock, endotoxin-induced multiple organ failure or disseminated intravascular coagulation, and/or cyclosporin-induced renal failure or hypertension, which contains a heteroaromatic ring-fused cyclopentene derivative of claim 5 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
- 13. A drug composition for the treatment of disorders such as hypertension, pulmonary hypertension, Raynaud's disease, acute renal failure, myocardial infarction, angina pectoris, cerebral infarction, cerebral vasospasm, arteriosclerosis, asthma, gastric ulcer, diabetes, restenosis, prostatauxe, endotoxin shock, endotoxin-induced multiple organ failure or disseminated intravascular coagulation, and/or cyclosporin-induced renal failure or hypertension, which contains a heteroaromatic ring-fused cyclopentene derivative of claim 6 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
- 14. A drug composition for the treatment of disorders such as hypertension, pulmonary hypertension, Raynaud's disease, acute renal failure, myocardial infarction, angina pectoris, cerebral infarction, cerebral vasospasm, arteriosclerosis, asthma, gastric ulcer, diabetes, restenosis, prostatauxe, endotoxin shock, endotoxin-induced multiple organ failure or disseminated intravascular coagulation, and/or cyclosporin-induced renal failure or hypertension, which contains a heteroaromatic ring-fused cyclopentene derivative of claim 7 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
- 15. A drug composition for the treatment of disorders such as hypertension, pulmonary hypertension, Raynaud's disease, acute renal failure, myocardial infarction, angina pectoris, cerebral infarction, cerebral vasospasm, arteriosclerosis, asthma, gastric ulcer, diabetes, restenosis, prostatauxe, endotoxin shock, endotoxin-induced multiple organ failure or disseminated intravascular coagulation, and/or cyclosporin-induced renal failure or hypertension, which contains a heteroaromatic ring-fused cyclopentene derivative of claim 8 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
- 16. A method for inducing vasodilation or bronchodilation in a patient in need thereof, comprising administering an effective amount of the heteroatomic ring-fused cyclopentene of claim 1.
- 17. A method for inducing vasodilation or bronchodilation in a patient in need thereof, comprising ad A method for inducing vasodilation or bronchodilation in a patient in need thereof, comprising administering an effective amount of the heteroaromatic ring-fused cyclopentene of claim 2.
- 18. A method for inducing vasodilation or bronchodilation in a patient in need thereof, comprising administering an effective amount of the heteroaromatic ring-fused cyclopentene of claim 3.
- 19. A method for inducing vasodilation or bronchodilation in a patient in need thereof, comprising administering an effective amount of the heteroaromatic ring-fused cyclopentene of claim 5.
- 20. A method for inducing vasodilation or bronchodilation in a patient in need thereof, comprising administering an effective amount of the heteroaromatic ring-fused cyclopentene of claim 6.
- 21. A method for inducing vasodilation or bronchodilation in a patient in need thereof, comprising administering an effective amount of the heteroaromatic ring-fused cyclopentene of claim 7.
- 22. A method for inducing vasodilation or bronchodilation in a patient in need thereof, comprising administering an effective amount of the heteroaromatic ring-fused cyclopentene of claim 8.
Priority Claims (4)
| Number |
Date |
Country |
Kind |
| 5-225100 |
Aug 1993 |
JPX |
|
| 5-281613 |
Oct 1993 |
JPX |
|
| 5-285677 |
Oct 1993 |
JPX |
|
| 6-085914 |
Mar 1994 |
JPX |
|
Parent Case Info
This application is a 371 of PCT/JP94/01357 filed Aug. 16, 1994, published as WO95/05374 Feb. 23, 1995, and a CIP of 08/296410 filed Aug. 26, 1994 now abandoned which was a continuation of 08/165,880 filed Dec. 14, 1993 now U.S. Pat. No. 5,389,620.
PCT Information
| Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
| PCT/JP94/01357 |
8/16/1994 |
|
|
2/20/1996 |
2/20/1996 |
| Publishing Document |
Publishing Date |
Country |
Kind |
| WO95/05374 |
2/23/1995 |
|
|
US Referenced Citations (1)
| Number |
Name |
Date |
Kind |
|
5389620 |
Ishikawa et al. |
Feb 1995 |
|
Foreign Referenced Citations (1)
| Number |
Date |
Country |
| WO 9308799 |
May 1993 |
WOX |
Continuations (1)
|
Number |
Date |
Country |
| Parent |
165880 |
Dec 1993 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
| Parent |
296410 |
Aug 1994 |
|
Patent Grant
5714479
